Pharmacyclics, Inc.

Les Laboratoires Servier

Ioana Kloos

Sriram Balasubramanian

Erik J Verner

Tarak D Mody

Joseph J Buggy

David J Loury

Norbert Purro

Stéphane Depil

Renata Robert

Anne Jacquet-Bescond

Marylore Chenel

Sylvain Fouliard

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof

N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterized in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.

Administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2- ylcarbonylamino]ethoxy}benzamide

Growing community of inventors

Rueil Malmaison, France

Ioana Kloos